Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cohort profile : the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD)

Salomon, Benita ; Grännö, Olle ; Bergemalm, Daniel ; Strid, Hans ; Carstens, Adam ; Hjortswang, Henrik ; Lundström, Maria Ling ; Hreinsson, Jóhann P. ; Almer, Sven LU orcid and Bresso, Franscesca , et al. (2025) In BMJ Open 15(5). p.1-9
Abstract

Purpose There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish Inception Cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures. Participants Patients aged ≥18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion. Findings to date In total, 367 patients with IBD (Crohn's disease, n=142; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without... (More)

Purpose There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish Inception Cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures. Participants Patients aged ≥18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion. Findings to date In total, 367 patients with IBD (Crohn's disease, n=142; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without gastrointestinal symptoms were recruited as a second control group. Biospecimens and clinical data were collected at inclusion and in patients with IBD also during follow-up to 10 years. Levels of faecal calprotectin and high-sensitivity C-reactive protein were higher in patients with IBD compared with symptomatic controls and healthy controls. Preliminary results highlight the potential of serum protein signatures and autoantibodies, as well as results from faecal markers, to differentiate between IBD and symptomatic controls in the cohort. During the first year of follow-up, 37% (53/142) of the patients with Crohn's disease, 24% (48/201) with ulcerative colitis and 4% (1/24) with IBD-U experienced an aggressive disease course. Future plans We have established an inception cohort enabling ongoing initiatives to collect and generate clinical data and multi-omics datasets. The cohort will allow analyses for translation into candidate biosignatures to support clinical decision-making in IBD. Additionally, the data will provide insights into mechanisms of disease pathogenesis.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
keywords
GASTROENTEROLOGY, Inflammatory bowel disease, Prognosis
in
BMJ Open
volume
15
issue
5
article number
e099218
pages
1 - 9
publisher
BMJ Publishing Group
external identifiers
  • scopus:105004588747
  • pmid:40328654
ISSN
2044-6055
DOI
10.1136/bmjopen-2025-099218
language
English
LU publication?
no
additional info
Publisher Copyright: © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.
id
e180b770-b630-44c4-8318-a001f958d5ed
date added to LUP
2025-06-08 20:01:50
date last changed
2025-07-06 22:52:25
@article{e180b770-b630-44c4-8318-a001f958d5ed,
  abstract     = {{<p>Purpose There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish Inception Cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures. Participants Patients aged ≥18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion. Findings to date In total, 367 patients with IBD (Crohn's disease, n=142; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without gastrointestinal symptoms were recruited as a second control group. Biospecimens and clinical data were collected at inclusion and in patients with IBD also during follow-up to 10 years. Levels of faecal calprotectin and high-sensitivity C-reactive protein were higher in patients with IBD compared with symptomatic controls and healthy controls. Preliminary results highlight the potential of serum protein signatures and autoantibodies, as well as results from faecal markers, to differentiate between IBD and symptomatic controls in the cohort. During the first year of follow-up, 37% (53/142) of the patients with Crohn's disease, 24% (48/201) with ulcerative colitis and 4% (1/24) with IBD-U experienced an aggressive disease course. Future plans We have established an inception cohort enabling ongoing initiatives to collect and generate clinical data and multi-omics datasets. The cohort will allow analyses for translation into candidate biosignatures to support clinical decision-making in IBD. Additionally, the data will provide insights into mechanisms of disease pathogenesis.</p>}},
  author       = {{Salomon, Benita and Grännö, Olle and Bergemalm, Daniel and Strid, Hans and Carstens, Adam and Hjortswang, Henrik and Lundström, Maria Ling and Hreinsson, Jóhann P. and Almer, Sven and Bresso, Franscesca and Eriksson, Carl and Grip, Olof and Blomberg, André and Marsal, Jan and Nikaein, Niloofar and Bakhtyar, Shoaib and Lindqvist, Carl Mårten and Hultgren Hörnquist, Elisabeth and Magnusson, Maria K. and Keita, Åsa V. and D'amato, Mauro and Repsilber, Dirk and Öhman, Lena and Söderholm, Johan D. and Carlson, Marie and Hedin, Charlotte R.H. and Kruse, Robert and Halfvarson, Jonas}},
  issn         = {{2044-6055}},
  keywords     = {{GASTROENTEROLOGY; Inflammatory bowel disease; Prognosis}},
  language     = {{eng}},
  month        = {{05}},
  number       = {{5}},
  pages        = {{1--9}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{BMJ Open}},
  title        = {{Cohort profile : the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD)}},
  url          = {{http://dx.doi.org/10.1136/bmjopen-2025-099218}},
  doi          = {{10.1136/bmjopen-2025-099218}},
  volume       = {{15}},
  year         = {{2025}},
}